Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

16 treatments under study, led by Secukinumab

Research Leaders

9 sponsors active, led by Novartis Pharmaceuticals

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 11 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

45%

5 trials in Phase 3/4

Results Transparency

60%

6 of 10 completed with results

Key Signals

6 with results100% success

Data Visualizations

Phase Distribution

11Total
Phase 1 (1)
Phase 2 (5)
Phase 3 (3)
Phase 4 (2)

Trial Status

Completed10
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 10 completed trials

Clinical Trials (11)

Showing 11 of 11 trials
Showing all 11 trials

Research Network

Common Treatments

  • Secukinumab2
  • Apremilast2
  • An2728 Vehicle1
  • Calcitriol1
  • Col1211

Active Sponsors

  • Novartis Pharmaceuticals3
  • Amgen2
  • Pfizer1
  • Federico II University1
  • GSK1

Top Investigators

Related Conditions

  • Psoriasis1
  • Obesity Body Mass Index 30 Kgm21
  • Psoriasistype Psoriasis1

Activity Timeline